{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:49:54Z","timestamp":1793162994479,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007613","name":"Ankara University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007613","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction\/objectives<\/jats:title>\n                    <jats:p>Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease in childhood. Subclinical inflammation is defined as persistently elevated acute phase reactants despite the absence of clinical attacks. The aim of this study was to determine the frequency of subclinical inflammation and its clinical predictors in pediatric FMF patients, and to assess treatment responses following therapeutic adjustments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medical records of FMF patients followed between January 2011 and February 2024 were retrospectively reviewed. Patients were grouped based on the presence of subclinical inflammation, and clinical features, genetics, and treatment responses were compared to identify risk factors for subclinical inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 572 pediatric FMF patients were included, of whom 89 (15.6%) exhibited subclinical inflammation. Patients with subclinical inflammation had significantly earlier disease onset, longer disease duration, numerically more frequent comorbid conditions, and more biallelic exon 10 mutations (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). In addition, arthritis and higher disease severity scores were detected as independent predictors of subclinical inflammation. Regarding treatment, 45% of patients with subclinical inflammation achieved resolution after colchicine dose adjustments. However, 55% required biologic therapies. Among biologic-treated patients, 87.7% showed normalization of inflammatory markers, whereas 12.3% continued to exhibit persistent inflammation; all of these patients had comorbid conditions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Subclinical inflammation is common in pediatric FMF patients. Our findings suggest that earlier disease onset, biallelic exon 10 mutations, arthritis, and higher disease severity scores are associated with persistent inflammation. Colchicine dose optimization effectively controls inflammation in nearly half of these patients, while biologic therapies, particularly IL-1 inhibitors, are effective for the remaining cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key points<\/jats:title>\n                    <jats:p>\n                      \u2022\n                      <jats:italic>Subclinical inflammation is common in pediatric FMF patients.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      \u2022\n                      <jats:italic>Early disease onset, biallelic exon 10 mutations, arthritis, and higher disease severity scores are associated with subclinical inflammation.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      \u2022\n                      <jats:italic>Colchicine dose adjustments are effective for nearly half of patients, while biologic therapies, particularly IL-1 inhibitors, are needed for the rest.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-026-08133-8","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T20:43:05Z","timestamp":1777063385000},"page":"3667-3674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Subclinical inflammation in pediatric familial Mediterranean fever: predictors and follow-up results of a retrospective single-center cohort study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2196-6440","authenticated-orcid":false,"given":"Onur","family":"Bah\u00e7eci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0306-7473","authenticated-orcid":false,"given":"Fatma","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1132-8082","authenticated-orcid":false,"given":"\u00d6zen","family":"Ta\u015f Aslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2583-8948","authenticated-orcid":false,"given":"Do\u011facan","family":"Sarisoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8405-8378","authenticated-orcid":false,"given":"Elif","family":"Erorhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6376-9189","authenticated-orcid":false,"given":"Zeynep Birsin","family":"\u00d6z\u00e7akar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"11","key":"8133_CR1","doi-asserted-by":"publisher","first-page":"9584","DOI":"10.3390\/ijms24119584","volume":"24","author":"M Lancieri","year":"2023","unstructured":"Lancieri M, Bustaffa M, Palmeri S, Prigione I, Penco F, Papa R et al (2023) An update on familial Mediterranean fever. Int J Mol Sci 24(11):9584. https:\/\/doi.org\/10.3390\/ijms24119584","journal-title":"Int J Mol Sci"},{"issue":"4","key":"8133_CR2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s0092-8674(00)80539-5","volume":"90","author":"I Aksentijevich","year":"1997","unstructured":"Aksentijevich I, Centola M, Deng Z, Sood R, Balow JE, Wood G et al (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90(4):797\u2013807. https:\/\/doi.org\/10.1016\/s0092-8674(00)80539-5","journal-title":"Cell"},{"issue":"1","key":"8133_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/ng0997-25","volume":"17","author":"A Bernot","year":"1997","unstructured":"Bernot A, Clepet C, Dasilva C, Devaud C, Petit JL, Caloustian C et al (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17(1):25\u201331. https:\/\/doi.org\/10.1038\/ng0997-25","journal-title":"Nat Genet"},{"issue":"5","key":"8133_CR4","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1365-2141.2009.07733.x","volume":"146","author":"JJ Chae","year":"2009","unstructured":"Chae JJ, Aksentijevich I, Kastner DL (2009) Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol 146(5):467\u2013478. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07733.x","journal-title":"Br J Haematol"},{"issue":"6","key":"8133_CR5","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.ard.2025.01.028","volume":"84","author":"S Ozen","year":"2025","unstructured":"Ozen S, Sa\u011f E, Oton T, G\u00fcl A, Sieiro Santos C, Bayraktar D et al (2025) EULAR\/PReS endorsed recommendations for the management of familial Mediterranean fever (FMF): 2024 update. Ann Rheum Dis 84(6):899\u2013909. https:\/\/doi.org\/10.1016\/j.ard.2025.01.028","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"8133_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/rheumatology\/ken509","volume":"48","author":"F Yal\u00e7inkaya","year":"2009","unstructured":"Yal\u00e7inkaya F, \u00d6zen S, \u00d6z\u00e7akar ZB, Aktay N, \u00c7akar N, D\u00fczova A et al (2009) A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 48(4):395\u2013398. https:\/\/doi.org\/10.1093\/rheumatology\/ken509","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"8133_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nrrheum.2010.181","volume":"7","author":"I Ben-Zvi","year":"2011","unstructured":"Ben-Zvi I, Livneh A (2011) Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 7(2):105\u2013112. https:\/\/doi.org\/10.1038\/nrrheum.2010.181","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"8133_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1080\/08880010500278681","volume":"22","author":"T Celkan","year":"2005","unstructured":"Celkan T, \u00c7elik M, Kasap\u00e7opur \u00d6, \u00d6zkan A, Apak H, Ocak S et al (2005) The anemia of familial Mediterranean fever disease. Pediatr Hematol Oncol 22(8):657\u2013665. https:\/\/doi.org\/10.1080\/08880010500278681","journal-title":"Pediatr Hematol Oncol"},{"issue":"2","key":"8133_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1515\/jpem.2006.19.2.155","volume":"19","author":"A Zung","year":"2006","unstructured":"Zung A, Barash G, Zadik Z, Barash J (2006) Familial Mediterranean fever and growth: effect of disease severity and colchicine treatment. J Pediatr Endocrinol Metab 19(2):155\u2013160. https:\/\/doi.org\/10.1515\/jpem.2006.19.2.155","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"3","key":"8133_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s10067-004-0874-y","volume":"23","author":"A D\u00fczova","year":"2004","unstructured":"D\u00fczova A, \u00d6zalt\u0131n F, \u00d6zon A, Be\u015fba\u015f N, Topalo\u011flu R, \u00d6zen S et al (2004) Bone mineral density in children with familial Mediterranean fever. Clin Rheumatol 23(3):230\u2013234. https:\/\/doi.org\/10.1007\/s10067-004-0874-y","journal-title":"Clin Rheumatol"},{"issue":"6","key":"8133_CR11","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/rheumatology\/kei279","volume":"45","author":"HJ Lachmann","year":"2006","unstructured":"Lachmann HJ, \u015eeng\u00fcl B, Yavuz\u015fen TU, Booth DR, Booth SE, Bybee A et al (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45(6):746\u2013750. https:\/\/doi.org\/10.1093\/rheumatology\/kei279","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"8133_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/RHU.0000000000001953","volume":"29","author":"H K\u0131sao\u011flu","year":"2023","unstructured":"K\u0131sao\u011flu H, Baba O, Kalyoncu M (2023) Genotype-phenotype associations of children with familial Mediterranean fever in a cohort consisting of M694V mutation and \u0131mplications for colchicine-resistant disease. J Clin Rheumatol 29(4):207\u2013213. https:\/\/doi.org\/10.1097\/RHU.0000000000001953","journal-title":"J Clin Rheumatol"},{"issue":"8","key":"8133_CR13","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00296-015-3227-z","volume":"35","author":"MT Bayram","year":"2015","unstructured":"Bayram MT, \u00c7ankaya T, Bora E, Kavuk\u00e7u S, \u00dclgenalp A, Soylu A et al (2015) Risk factors for subclinical inflammation in children with familial Mediterranean fever. Rheumatol Int 35(8):1393\u20131398. https:\/\/doi.org\/10.1007\/s00296-015-3227-z","journal-title":"Rheumatol Int"},{"issue":"6","key":"8133_CR14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1136\/annrheumdis-2015-208671","volume":"75","author":"E Demirkaya","year":"2016","unstructured":"Demirkaya E, Acikel C, Hashkes P, Gattorno M, G\u00fcl A, \u00d6zdo\u011fan H et al (2016) Development and initial validation of \u0130nternational severity scoring system for familial Mediterranean fever (ISSF). Ann Rheum Dis 75(6):1051\u20131056. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208671","journal-title":"Ann Rheum Dis"},{"key":"8133_CR15","unstructured":"World Health Organization (WHO) Growth reference data for 5\u201319 years. Available at: https:\/\/www.who.int\/tools\/growth-reference-data-for-5to19-years\/indicators\/bmi-for-age Accessed 10 September 2025"},{"issue":"1","key":"8133_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/ard.61.1.79","volume":"61","author":"C Korkmaz","year":"2002","unstructured":"Korkmaz C, \u00d6zdogan H, Kasap\u00e7opur O, Yaz\u0131c\u0131 H (2002) Acute phase response in familial Mediterranean fever. Ann Rheum Dis 61(1):79\u201381. https:\/\/doi.org\/10.1136\/ard.61.1.79","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"8133_CR17","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2015-208690","volume":"75","author":"S Ozen","year":"2016","unstructured":"Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G et al (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644\u2013651. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208690","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8133_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/rheumatology\/keaa378","volume":"60","author":"H Babaoglu","year":"2021","unstructured":"Babaoglu H, Armagan B, Bodakci E, Satis H, Atas N, Sari A et al (2021) Predictors of persistent inflammation in familial Mediterranean fever and association with damage. Rheumatology (Oxford) 60(1):333\u2013339. https:\/\/doi.org\/10.1093\/rheumatology\/keaa378","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"8133_CR19","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/mr\/roab054","volume":"32","author":"D Gezgin Y\u0131ld\u0131r\u0131m","year":"2022","unstructured":"Gezgin Y\u0131ld\u0131r\u0131m D, Esmeray \u015eenol P, S\u00f6ylemezo\u011flu O (2022) Predictors of persistent inflammation in children with familial Mediterranean fever. Mod Rheumatol 32(4):803\u2013807. https:\/\/doi.org\/10.1093\/mr\/roab054","journal-title":"Mod Rheumatol"},{"issue":"4 Suppl 67","key":"8133_CR20","first-page":"S87","volume":"29","author":"F Yal\u00e7\u0131nkaya","year":"2011","unstructured":"Yal\u00e7\u0131nkaya F, \u00d6z\u00e7akar ZB, Tany\u0131ld\u0131z M, Elhan AH (2011) Familial Mediterranean fever in small children in Turkey. Clin Exp Rheumatol 29(4 Suppl 67):S87-90","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"8133_CR21","doi-asserted-by":"publisher","first-page":"438","DOI":"10.14744\/nci.2020.96636","volume":"7","author":"F Demir","year":"2020","unstructured":"Demir F (2020) The musculoskeletal system manifestations in children with familial Mediterranean fever. North Clin Istanb 7(5):438\u2013442. https:\/\/doi.org\/10.14744\/nci.2020.96636","journal-title":"North Clin Istanb"},{"issue":"11","key":"8133_CR22","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1111\/imj.16495","volume":"54","author":"S Yenig\u00fcn","year":"2024","unstructured":"Yenig\u00fcn S, Ayla AY, Y\u00fczba\u015f\u0131o\u011flu MB, Ba\u015fp\u0131nar SN, Erg\u00fcn S, Karabicek A et al (2024) Characteristics of arthritis in patients with familial Mediterranean fever. Intern Med J 54(11):1802\u20131808. https:\/\/doi.org\/10.1111\/imj.16495","journal-title":"Intern Med J"},{"issue":"3","key":"8133_CR23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/rheumatology\/kead242","volume":"63","author":"ED Batu","year":"2024","unstructured":"Batu ED, Sener S, Arslanoglu Aydin E, Aliyev E, Bagrul I, Turkmen S et al (2024) A score for predicting colchicine resistance at the time of diagnosis in familial Mediterranean fever: data from the TURPAID registry. Rheumatology 63(3):791\u2013797. https:\/\/doi.org\/10.1093\/rheumatology\/kead242","journal-title":"Rheumatology"},{"key":"8133_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2024.1421353","volume":"12","author":"A Chaaban","year":"2024","unstructured":"Chaaban A, Yassine H, Hammoud R, Kanaan R, Karam L, Ibrahim JN (2024) A narrative review on the role of cytokines in the pathogenesis and treatment of familial Mediterranean fever: an emphasis on pediatric cases. Front Pediatr 12. https:\/\/doi.org\/10.3389\/fped.2024.1421353","journal-title":"Front Pediatr"},{"issue":"5","key":"8133_CR25","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.20240068","volume":"70","author":"I Atik","year":"2024","unstructured":"Atik I, Atik S (2024) Relationship between sacroiliitis and inflammatory markers in familial Mediterranean fever. Rev Assoc Med Bras (1992) 70(5). https:\/\/doi.org\/10.1590\/1806-9282.20240068","journal-title":"Rev Assoc Med Bras (1992)"},{"issue":"11","key":"8133_CR26","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1093\/rheumatology\/keaa121","volume":"59","author":"E Sa\u011f","year":"2020","unstructured":"Sa\u011f E, Akal F, Atalay E, Ak\u00e7a UK, Demir S, Demirel D et al (2020) Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry. Rheumatology (Oxford) 59(11):3324\u20133329. https:\/\/doi.org\/10.1093\/rheumatology\/keaa121","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"8133_CR27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/children12020232","volume":"12","author":"NM Sav","year":"2025","unstructured":"Sav NM, Altinsoy HB, Turen B, Gokce A (2025) Arterial stiffness and subclinical inflammation in children with familial Mediterranean fever: a comprehensive analysis. Children 12(2):232. https:\/\/doi.org\/10.3390\/children12020232","journal-title":"Children"},{"key":"8133_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152211","volume":"61","author":"Y Levinsky","year":"2023","unstructured":"Levinsky Y, Azani L, Shkalim Zemer V, Chodick G, Tal R, Harel L et al (2023) Adherence to colchicine prophylaxis among patients with familial Mediterranean fever treated with interleukin-1 inhibitors. Semin Arthritis Rheum 61. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152211","journal-title":"Semin Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08133-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08133-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08133-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:25:48Z","timestamp":1780982748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08133-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["8133"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08133-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was approved by the local ethics committee (approval number: 2025000463\u20133\/11.08.2025) in accordance with ethical principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Reviewer disclosures"}}]}}